OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
 Annual Meeting - EconoTimes)
EAGAN, Minn., May 31, 2017 -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced melanoma/triple negative breast cancer, will be presented at the 2017 ASCO Annual Meeting, taking place in Chicago, IL, June 2-6, 2017. The ASCO presentation details are as follows:
| Session Date & Time: | Monday, June 5, 2017, 8:00 AM – 11:30 AM Central Time |
| Session: | Developmental Therapeutics—Immunotherapy |
| Presentation Title: | A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease. |
| Session Location: | McCormick Place, Hall A, Poster Board #193a |
| Abstract No.: | TPS3105 |
Biothera announced earlier this year initiation of patient dosing in the Phase 2 study, which is evaluating the Company’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada). The multi-center, open-label study is anticipated to enroll up to 71 patients who have tested positive for a biomarker that may identify patients with higher probability of responding to Imprime PGG combination therapy. Additional information on the trial is available by visiting clinicaltrials.gov.
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact: David Walsh Communications Biothera Pharmaceuticals, Inc. 651-256-4606 [email protected]
